
Hiroaki Saito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2789539/publications.pdf Version: 2024-02-01



HIROAKI SAITO

#	Article	IF	CITATIONS
1	European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy, 2012, 45, 51-59.	1.8	356
2	Automatic detection of erosions and ulcerations in wireless capsule endoscopy images based on a deep convolutional neural network. Gastrointestinal Endoscopy, 2019, 89, 357-363.e2.	1.0	217
3	Novel computer-assisted diagnosis system for endoscopic disease activity in patients with ulcerative colitis. Castrointestinal Endoscopy, 2019, 89, 416-421.e1.	1.0	157
4	Automatic detection and classification of protruding lesions in wireless capsule endoscopy images based on a deep convolutional neural network. Gastrointestinal Endoscopy, 2020, 92, 144-151.e1.	1.0	124
5	Artificial intelligence using a convolutional neural network for automatic detection of smallâ€bowel angioectasia in capsule endoscopy images. Digestive Endoscopy, 2020, 32, 382-390.	2.3	114
6	Automatic detection of blood content in capsule endoscopy images based on a deep convolutional neural network. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1196-1200.	2.8	77
7	Clinical usefulness of a deep learningâ€based system as the first screening on smallâ€bowel capsule endoscopy reading. Digestive Endoscopy, 2020, 32, 585-591.	2.3	74
8	Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan. JAMA Network Open, 2019, 2, e192834.	5.9	45
9	Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016. Health Policy, 2020, 124, 727-735.	3.0	42
10	Automatic detection of various abnormalities in capsule endoscopy videos by a deep learning-based system: a multicenter study. Gastrointestinal Endoscopy, 2021, 93, 165-173.e1.	1.0	42
11	Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis. BMJ Open, 2019, 9, e028805.	1.9	40
12	Pharmaceutical Company Payments to Executive Board Members of Professional Medical Associations in Japan. JAMA Internal Medicine, 2019, 179, 578.	5.1	35
13	Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan. PLoS ONE, 2020, 15, e0239610.	2.5	34
14	Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan. JAMA Network Open, 2019, 2, e193817.	5.9	27
15	Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer Journal, 2022, 12, 54.	6.2	26
16	Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. International Urogynecology Journal, 2021, 32, 443-451.	1.4	25
17	Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 819-826.	4.5	23
18	Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngology - Head and Neck Surgery, 2022, 166, 869-876.	1.9	19

Hiroaki Saito

#	Article	lF	CITATIONS
19	Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clinical Microbiology and Infection, 2022, 28, 460-462.	6.0	19
20	Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan. Clinical Microbiology and Infection, 2019, 25, 1304-1306.	6.0	18
21	Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. Health Policy, 2021, 125, 320-326.	3.0	18
22	Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019. International Journal of Environmental Research and Public Health, 2022, 19, 7417.	2.6	17
23	Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver International, 2021, 41, 464-469.	3.9	15
24	Automatic anatomical classification of colonoscopic images using deep convolutional neural networks. Gastroenterology Report, 2021, 9, 226-233.	1.3	11
25	Letter to the editor: Are clinical practice guidelines for hepatitis C by the American Association for the Study of Liver Diseases and Infectious Diseases Society of America evidence based? Financial conflicts of interest and assessment of quality of evidence and strength of recommendations. Hepatology, 2022, 75, 1052-1054.	7.3	11
26	Nivolumab-induced Pancreatitis: An Immune-related Adverse Event. Radiology, 2019, 293, 521-521.	7.3	10
27	Premature death associated with long-term evacuation among a vulnerable population after the Fukushima nuclear disaster. Medicine (United States), 2019, 98, e16162.	1.0	10
28	Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 228-230.	3.7	9
29	The subâ€classification of type B2 vessels according to the magnifying endoscopic classification of the Japan Esophageal Society. Digestive Endoscopy, 2020, 32, 49-55.	2.3	9
30	Helicobacter pylori Infection Mass Screening for Children and Adolescents: a Systematic Review of Observational Studies. Journal of Gastrointestinal Cancer, 2021, 52, 489-497.	1.3	9
31	Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians. International Journal of Environmental Research and Public Health, 2022, 19, 3478.	2.6	9
32	High internal radiation exposure associated with low socio-economic status six years after the Fukushima nuclear disaster. Medicine (United States), 2019, 98, e17989.	1.0	8
33	The risks and characteristics of the delayed bleeding after endoscopic submucosal dissection for early gastric carcinoma in cases with anticoagulants. Scandinavian Journal of Gastroenterology, 2020, 55, 1253-1260.	1.5	8
34	Pharmaceutical Company Payments to the Professors of Orthopaedic Surgery Departments in Japan. Journal of Bone and Joint Surgery - Series A, 2020, 102, e39.	3.0	8
35	Pharmaceutical Company Payments to Japanese Government Drug Regulation Committee Members. Clinical Pharmacology and Therapeutics, 2020, 108, 1049-1054.	4.7	8
36	Secondary aortoenteric fistula possibly associated with continuous physical stimulation: a case report and review of the literature. Journal of Medical Case Reports, 2019, 13, 61.	0.8	7

Hiroaki Saito

#	Article	IF	CITATIONS
37	New physician specialty training system impact on distribution of trainees in Japan. Public Health, 2020, 182, 143-150.	2.9	7
38	Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies. Clinical Microbiology and Infection, 2021, 27, 805-807.	6.0	7
39	Comparative risk assessment of non-communicable diseases by evacuation scenario– a retrospective study in the 7 years following the Fukushima Daiichi nuclear power plant accident. Clobal Health Action, 2021, 14, 1918886.	1.9	7
40	Factors associated with inaccurate size estimation of colorectal polyps: A multicenter crossâ€sectional study. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2224-2229.	2.8	6
41	Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension. Medicine (United States), 2021, 100, e24816.	1.0	6
42	How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan. Frontiers in Public Health, 2021, 9, 762637.	2.7	6
43	Transparency Is Not Enough: How Can We Improve the Management of Financial Conflicts of Interest Between Pharma and Healthcare Sectors?. Clinical Pharmacology and Therapeutics, 2021, 110, 289-291.	4.7	5
44	Negative Aspects of the Regional Quota System in Japan. JMA Journal, 2019, 2, 85-86.	0.8	5
45	The long term participation trend for the colorectal cancer screening after the 2011 triple disaster in Minamisoma City, Fukushima, Japan. Scientific Reports, 2021, 11, 23851.	3.3	5
46	Successful institutional care for behavioral and psychological symptoms of dementia in a repopulated area after the 2011 Fukushima disaster: A case report. Clinical Case Reports (discontinued), 2018, 6, 2266-2270.	0.5	3
47	Difficulty in diagnosing mild cases of COVIDâ€19 without respiratory symptoms during the Novel Coronavirus Pandemic: Careful monitoring needed for patients with persistent upper gastrointestinal symptoms. Clinical Case Reports (discontinued), 2020, 8, 2787-2790.	0.5	3
48	Massive esophageal hemorrhage after a MitraClip procedure successfully treated by balloon compression. Clinical Journal of Gastroenterology, 2020, 13, 693-696.	0.8	2
49	Transparency of clinical evidence for medical devices in Europe. Lancet, The, 2019, 393, 1693.	13.7	1
50	Immune-Mediated Colitis Induced by Pembrolizumab. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	1
51	Patient Outcomes and Environment May Affect Adherence to Helicobacter pylori Testing. Clinical Gastroenterology and Hepatology, 2021, 19, 1297-1298.	4.4	1
52	Posterior Mediastinitis Caused by Esophageal Anisakiasis. Clinical Gastroenterology and Hepatology, 2021, 19, A30.	4.4	1
53	A case of duodenal polyp at superior duodenal angle successfully treated by cap-assisted endoscopic mucosal resection. VideoGIE, 2020, 5, 681-683.	0.7	0
54	Response to "Strictness and Transparency in Approval Process of Medical Products: Japanese Situation― Clinical Pharmacology and Therapeutics, 2021, 109, 291-291.	4.7	0

#	Article	IF	CITATIONS
55	Small But Invasive Colorectal Cancer: Do Not Miss It. Journal of the Canadian Association of Gastroenterology, 2021, 4, 257-258.	0.3	0
56	Acute Gastritis During Immune Check Point Inhibitor Treatment. Journal of the Canadian Association of Gastroenterology, 0, , .	0.3	0